

CITATION REPORT

List of articles citing

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

DOI: 10.1016/s0895-7061(02)02957-6

American Journal of Hypertension, 2002, 15, 709-16.

Source: <https://exaly.com/paper-pdf/34254559/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
328	Eplerenone--a novel selective aldosterone blocker. 2002 , 36, 1567-76		34
327	Eplerenone: a new aldosterone receptor antagonist--are the FDA's restrictions appropriate?. 2002 , 4, 441-5		26
326	Clinical implications of aldosterone blockade. 2002 , 144, S12-8		26
325	Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. <i>Current Hypertension Reports</i> , 2003 , 5, 122-5	4.7	17
324	RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. <i>Current Hypertension Reports</i> , 2003 , 5, 408-17	4.7	54
323	Aldosterone receptor antagonists: focus on eplerenone. 2003 , 18, 54-9		1
322	Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. 2003 , 92, 38-42		102
321	[Management of high blood pressure and cardiac insufficiency. New drugs and therapeutic concepts]. 2003 , 32, 54-9		
320	Aldosterone receptor antagonists for hypertension: what do they offer?. 2003 , 63, 1963-72		9
319	Aldosterone receptor antagonists: biology and novel therapeutical applications. 2003 , 26, 788-98		4
318	Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. 2003 , 25, 2388-404		62
317	The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. 2003 , 25, 2647-68		21
316	Primary aldosteronism - treatment options. 2003 , 13 Suppl A, S102-8		22
315	Efficacy of low-dose spironolactone in subjects with resistant hypertension. <i>American Journal of Hypertension</i> , 2003 , 16, 925-30	2.3	383
314	Oportunidades clínicas del bloqueo aldosterónico en la hipertensión arterial. 2003 , 20, 335-339		
313	Aldosterone in chronic kidney and cardiac disease. 2003 , 14, 2395-401		106
312	Novel pharmacological treatments for heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 1791-801	5.9	11

- 311 Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?. **2003**, 4, 1605-7
- 310 Management of glomerular proteinuria: a commentary. **2003**, 14, 3217-32 166
- 309 Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. **2003**, 41, 1021-6 242
- 308 Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. **2003**, 18, 1984-92 39
- 307 Eplerenone: cardiovascular protection. **2003**, 107, 2512-8 118
- 306 Aldosterone resurgens--letter from EPHEBUS. **2003**, 88, 2373-5 4
- 305 Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. **2003**, 144, 2208-13 293
- 304 Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. **2003**, 88, 3867-73 31
- 303 Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. **2003**, 12, 153-8 12
- 302 Aldosterone in renal disease. **2003**, 12, 159-64 30
- 301 Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). **2003**, 5, 102-18 29
- 300 Bibliography Current World Literature. **2003**, 10, 205-228
- 299 Emerging drugs in the management of hypertension. **2003**, 8, 377-88 10
- 298 Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. **2003**, 5, 354-63 24
- 297 Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. *Hypertension Research*, **2004**, 27, 781-9 4-7 39
- 296 Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. **2004**, 17, 217-20 26
- 295 Novel antihypertensive agents. *Expert Opinion on Investigational Drugs*, **2004**, 13, 987-98 5-9
- 294 Role of aldosterone blockade in the management of hypertension and cardiovascular disease. **2004**, 143, 90-104 3

293	Eplerenone in hypertension. 2004 , 5, 2573-81		7
292	Distinguishing the antihypertensive and electrolyte effects of eplerenone. 2004 , 89, 2736-40		101
291	Role of the selective aldosterone receptor blockers in arterial hypertension. 2004 , 5, 23-5		4
290	Aldosterone and cardiovascular remodelling: focus on myocardial failure. 2004 , 5, 3-13		12
289	Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. 2004 , 43, 41-7		166
288	The many targets of aldosterone. 2004 , 43, 938-40		16
287	Aldosterone blockade in cardiovascular disease. 2004 , 90, 1229-34		36
286	Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. 2004 , 24, 750-6		15
285	Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. 2004 , 93, 990-6		140
284	Aldosterone in heart failure: pathophysiology and treatment. 2004 , 1, 171-5		13
283	Mineralocorticoid receptor antagonists and hypertension: is there a rationale?. <i>Current Hypertension Reports</i> , 2004 , 6, 279-87	4-7	11
282	The use of selective aldosterone antagonists. <i>Current Hypertension Reports</i> , 2004 , 6, 342-5	4-7	5
281	Aldosterone and aldosterone antagonism in systemic hypertension. <i>Current Hypertension Reports</i> , 2004 , 6, 195-200	4-7	12
280	The evolution of aldosterone antagonists. 2004 , 217, 27-31		121
279	Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. 2004 , 217, 151-65		29
278	Aldosterone target organ protection by eplerenone. 2004 , 217, 229-38		50
277	Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. 2004 , 147, 564-72		16
276	The use of aldosterone receptor blockers in the treatment of hypertension. 2004 , 6, 632-5		2

275	Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. 2004 , 6, 175-83; quiz 184-5			34
274	Use of aldosterone antagonists in resistant hypertension. 2004 , 6, 458-60			10
273	Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. 2004 , 30, 311-8			11
272	Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease. 2004 , 44, 604-10; quiz 610-1			6
271	Current World Literature. 2004 , 13, 243-274			
270	New treatment option for heart failure patients: eplerenone. 2004 , 19, 390-5			
269	Hipertensi3 arterial y riesgo cardiovascular en el a3 2004. 2005 , 5, 24A-34A			
268	The risks and benefits of aldosterone antagonists. 2005 , 2, 65-71			15
267	Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. <i>Current Hypertension Reports</i> , 2005 , 7, 186-92	4-7		9
266	The role of aldosterone antagonists in the management of resistant hypertension. <i>Current Hypertension Reports</i> , 2005 , 7, 343-7	4-7		28
265	Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. 2005 , 10, 23-9			135
264	Antihypertensive therapy: role of aldosterone antagonists. 2005 , 11, 2235-42			8
263	Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. 2005 , 46, 313-20			27
262	Aldosterone and Mineralocorticoids. 2005 , 117-122			
261	Diagnosis of adenomatous primary aldosteronism in a patient with severe hypertension. 2005 , 1, 111-5; quiz following 115			2
260	The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. 2005 , 67, 1714-22			14
259	Diuretics for hypertension. 2005 , 112, e127-9			13
258	Eplerenone: a review of its use in essential hypertension. 2005 , 5, 51-69			24

257	New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia. 2005 , 4, 677-88		3
256	The aldosterone antagonist and facultative diuretic eplerenone: a critical review. <i>European Journal of Internal Medicine</i> , 2005 , 16, 3-11	3.9	20
255	The aldosterone antagonist and facultative diuretic eplerenone: A critical review. <i>European Journal of Internal Medicine</i> , 2005 , 16, 145-153	3.9	
254	Effects of eplerenone versus losartan in patients with low-renin hypertension. 2005 , 150, 426-33		87
253	Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?. 2005 , 3, 497-512		0
252	Eplerenone reduces deaths from heart failure after a heart attack and effectively treats hypertension. 2006 , 22, 1-4		
251	Resistant or difficult-to-treat hypertension. 2006 , 8, 181-6		20
250	[Primary hyperaldosteronism: should we pose its systematic detection at health centres?]. 2006 , 37, 104-7		
249	Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. 2006 , 119, 912-9		98
248	Management of cirrhotic ascites: physiological basis of diuretic action. <i>European Journal of Internal Medicine</i> , 2006 , 17, 8-19	3.9	13
247	Eplerenone: a selective aldosterone blocker. 2003 , 21, 169-84		16
246	Does eplerenone have a future in the management of hypertension in Europe?. 2006 , 20, 829-32		4
245	[Modern pharmacological aspects of hyperaldosteronism therapy]. 2006 , 47, 953-9		3
244	Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?. <i>Current Hypertension Reports</i> , 2006 , 8, 262-8	4.7	16
243	Mecanismo de acción de la eplerenona. 2006 , 6, 31B-47B		
242	Use of aldosterone antagonists in resistant hypertension. 2006 , 48, 387-96		47
241	Primary aldosteronism: diagnostic and treatment strategies. 2006 , 2, 198-208; quiz, 1 p following 230		151
240	Aldosteronism and hypertension. 2006 , 1, 1039-45		51

239	Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. 2006 , 48, 1050-7	106
238	Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. 2006 , 1, 940-51	298
237	Aldosterone antagonists in the treatment of heart failure. 2006 , 63, 49-58	12
236	The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease. 2006 , 2, 21-32	1
235	The pharmacological treatment of primary aldosteronism. 2006 , 7, 563-73	9
234	Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. 2007 , 8, 3053-9	12
233	Non-steroidal mineralocorticoid receptor antagonists. 2007 , 17, 17-23	15
232	Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension. 2007 , 293, F139-47	29
231	Role of radiology in the management of primary aldosteronism. 2007 , 27, 1145-57	40
230	The risks and benefits of therapy with aldosterone receptor antagonist therapy. 2007 , 2, 71-7	11
229	Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. 2007 , 25, 639-47	25
228	The future of antihypertensive treatment. 2007 , 14, 121-34	51
227	Update of diuretics in the treatment of hypertension. 2007 , 14, 154-60	35
226	Hyperaldost�onisme primaire. 2007 , 4, 1-7	2
225	Aldosterone antagonist therapy in resistant hypertension. 2007 , 25, 747-50	24
224	Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. 2007 , 9, 19-24	24
223	Eplerenone suppresses neointimal formation after coronary stent implantation in swine, a reply. 2007 , 115, 99-100	3
222	Antialdosteronici vecchi e nuovi nel trattamento dell'ipertensione e dello scompenso cardiaco. 2007 , 8, 177-183	

221	Primary Hyperaldosteronism and Other Forms of Mineralocorticoid Hypertension. 2007 , 809-825		1
220	Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development. 2007 , 2, 31-58		45
219	Novel Drug Treatments for Hypertension. 2007 , 1049-1060		1
218	Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. 2007 , 566, 153-9		32
217	Prediction of successful outcome in patients with primary aldosteronism. 2007 , 8, 314-21		3
216	Mineralocorticoid receptor antagonists. <i>Current Hypertension Reports</i> , 2007 , 9, 45-52	4-7	5
215	The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. <i>Current Hypertension Reports</i> , 2007 , 9, 98-105	4-7	14
214	A comparison of the aldosterone-blocking agents eplerenone and spironolactone. 2008 , 31, 153-8		149
213	Eplerenone in the treatment of Gitelman's syndrome. 2008 , 38, 377		10
212	Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. 2008 , 4, 44-52		21
211	Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. 2008 , 93, 3266-81		1231
210	Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats. 2008 , 57, 155-60		15
209	Management of hypertension in the outpatient setting. 2008 , 35, 451-73, vi		3
208	A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. 2008 , 29, 133-54		144
207	Review: Aldosterone Antagonists. 2008 , 8, 215-219		1
206	Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. 2008 , 9, 509-15		94
205	[Pharmacology profile and clinical findings of Selara Tablets (eplerenone)]. 2008 , 132, 227-35		
204	Nuclear Receptors as Targets in Cardiovascular Diseases. 2008 , 409-429		2

203	Resistant hypertension: identifying causes and optimizing treatment regimens. 2008 , 101, 166-73	14
202	. 2008 ,	14
201	The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. 2009 , 15 Suppl 1, 1-20	286
200	Safety and Efficacy of Eplerenone in the Management of Essential Hypertension. 2009 , 1, CMT.S2211	
199	The clinical pharmacology of eplerenone. 2009 , 5, 425-32	17
198	Aldosterone in clinical nephrology--old hormone, new questions. 2009 , 24, 2316-21	7
197	Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. 2009 , 54, 1674-82	100
196	Aldosteronomas--state of the art. 2009 , 89, 1241-53	24
195	Aldosterone-receptor antagonism in hypertension. 2009 , 27, 680-91	66
194	Diuretics: an update on the pharmacology and clinical uses. 2009 , 16, 74-85	13
193	Spirolactone for all hypertensive patients?. 2010 , 28, 13-4	
192	Eplerenone: Selective Aldosterone Antagonist. 2010 , 359-381	
191	Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. 2010 , 53, 5970-8	36
190	Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. 2010 , 53, 5979-8002	78
189	The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. 2010 , 157, 282-7	46
188	. 2010 ,	25
187	Primary aldosteronism: an update. 2010 , 5, 389-402	
186	Reducing Cardiovascular Risk in Patients following MI with Eplerenone. 2010 , 2, CMT.S5231	

185	Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. 2010 , 56, 780-800		327
184	Review article: eplerenone: an underused medication?. 2010 , 15, 318-25		6
183	A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. 2010 , 285, 29932-40		122
182	Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. 2010 , 24, 387-94		24
181	The role of aldosteronism in causing obesity-related cardiovascular risk. 2010 , 28, 517-27		53
180	Novel therapeutic targets for hypertension. 2010 , 7, 431-41		89
179	Aldosterone and arterial hypertension. 2010 , 6, 83-93		93
178	Treatment of primary aldosteronism. 2010 , 24, 923-32		17
177	Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice. 2010 , 208, 26-7		4
176	Emerging drugs which target the renin-angiotensin-aldosterone system. 2011 , 16, 619-30		23
175	Endocrine hypertension--current understanding and comprehensive management review. <i>European Journal of Internal Medicine</i> , 2011 , 22, 433-40	3.9	12
174	Long-term use of aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis. 2011 , 2011, 368140		4
173	Changes in the perceived epidemiology of primary hyperaldosteronism. 2011 , 2011, 162804		34
172	Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. 2011 , 7, 353-63		31
171	A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. 2011 , 29, 980-90		151
170	Treatment considerations with aldosterone receptor antagonists. 2011 , 13, 65-9		10
169	Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. 2011 , 13, 644-8		54
168	What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?. 2011 , 13, 520-6		3

167	The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. 2011 , 9, 180	40
166	Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. 2011 , 32, 2739-47	83
165	Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. 2011 , 124, 1945-55	145
164	Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension. 2011 , 33, 538-47	9
163	Eplerenone for the treatment of cardiovascular disorders. 2012 , 10, 831-8	3
162	Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. 2012 , 14, 668-75	60
161	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. 2012 , 33, 2782-95	121
160	Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. 2012 , 59, 1164-9	34
159	SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. 2012 , 59, 458-64	26
158	Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. 2012 , 18, 265-81	42
157	Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure. 2012 , 32, 827-37	8
156	Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. 2012 , 12, 19	23
155	Eplerenone is not superior to older and less expensive aldosterone antagonists. 2012 , 125, 817-25	24
154	[Hypertension-induced fibrosis: a balance story]. 2012 , 61, 150-5	4
153	Chronic kidney disease and congestive heart failure management: cardioneurologist's role. 2012 , 24, 82-94	1
152	Key advances in antihypertensive treatment. 2012 , 9, 276-85	39
151	Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. 2012 , 7, 1385-403	144
150	Aldosterone in heart disease. <i>Current Hypertension Reports</i> , 2012 , 14, 125-9	4-7 14

149	Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. 2012 , 350, 310-7	110
148	Primary aldosteronism: from bench to bedside. 2012 , 41, 31-9	11
147	Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. 2013 , 73, 1451-62	10
146	New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. 2013 , 14, 285-9	11
145	Aldosterone synthase inhibition in humans. 2013 , 28, 36-43	66
144	Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword. 2013 , 31, 1948-51	
143	Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. 2013 , 37, 557-66	26
142	Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. 2013 , 31, 3-15	73
141	Antihypertensive agents. 2013 , 208-220	
140	Aldosterone receptor antagonists: current perspectives and therapies. 2013 , 9, 321-31	25
139	[Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage]. 2014 , 142, 61-71	2
138	Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the Styrian Hypertension Study. 2014 , 16, 289-94	10
137	Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. 2014 , 16, 143-50	19
136	Aldosterone synthase inhibitors in hypertension: current status and future possibilities. 2014 , 3, 2048004014522440	
135	Aldosterone and volume management in hypertensive heart disease. 2014 , 34, 323-32	8
134	Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. <i>Current Hypertension Reports</i> , 2014 , 16, 414	4-7 24
133	High-dose spironolactone changes renin and aldosterone levels in acutely decompensated heart failure. 2014 , 56, e463-e470	6
132	Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders. 2014 , 4, 1083-119	9

131	Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. 2014 , 177, 219-28	29
130	Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. 2014 , 15, 605-21	39
129	Evoluci3n de la enfermedad cardiorrenal bajo la supresi3n cr3tica del sistema renina-angiotensina. 2014 , 31, 14-22	
128	Comparison of agents that affect aldosterone action. 2014 , 34, 285-306	23
127	Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. 2015 , 11, 235-9	18
126	Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!. 2015 , 2, 3	5
125	Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. 2015 , 200, 25-9	75
124	CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. 2015 , 769, 266-73	47
123	Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?. 2015 , 47, 1000-6	13
122	Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. 2015 , 26, 468-75	51
121	Hypertension in High Risk African Americans. 2015 ,	
120	Pharmacological treatment of aldosterone excess. 2015 , 154, 120-33	22
119	Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension. 2015 , 200, 8-11	11
118	An update of the blockade of the renin angiotensin aldosterone system in clinical practice. 2015 , 16, 2283-92	19
117	Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. 2015 , 761, 226-34	62
116	Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A. 2016 , 11, e0153635	16
115	Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?. 2016 , 67, 26-38	26
114	A validated stability-indicating ultra performance liquid chromatography method for the determination of potential process-related impurities in eplerenone. 2016 , 39, 2907-18	4

113	Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation. 2016 , 163, 68-76	12
112	Renal denervation in hypertensive patients not on blood pressure lowering drugs. 2016 , 105, 755-62	17
111	Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. 2016 , 18, 28-37	48
110	Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. 2017 , 243, 271-305	60
109	Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials. 2016 , 10, 671-82	13
108	Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure. 2016 , 67, 424-9	37
107	Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. 2016 , 68, 49-75	167
106	Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. <i>Hypertension Research</i> , 2016 , 39, 133-7	4-7 40
105	Diuretics in the treatment of hypertension. 2016 , 31, 2223-2233	32
104	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. 2016 , 101, 1889-916	1240
103	Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. 2016 , 27, 78-85	27
102	Primary Mineralocorticoid Excess Disorders and Hypertension. 2016 , 1871-1891.e6	
101	Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease. 2017 , 57, 739-746	5
100	Eplerenone for hypertension. 2017 , 2, CD008996	16
99	Protein Phosphatase 1e enhances renal aldosterone signaling via mineralocorticoid receptor stabilization. 2017 , 450, 74-82	5
98	30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. 2017 , 234, T125-T140	109
97	Steroidal Mineralocorticoid Receptor Antagonists: Synthesis and Biology. 2017 , 2, 175-189	2
96	Salt-dependent Blood Pressure in Human Aldosterone Synthase-Transgenic Mice. 2017 , 7, 492	12

95	Genomic and rapid effects of aldosterone: what we know and do not know thus far. 2017 , 22, 65-89		32
94	Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. 2017 , 136, e200-e231		116
93	Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial. 2017 , 105, 212-217		5
92	Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension. <i>American Journal of Hypertension</i> , 2017 , 30, 103-109	2.3	34
91	Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. 2017 , 47, 1090-1103		19
90	Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. 2017 , 13, 403-411		14
89	Resistant Hypertension: Which Agent?. 2018 , 27, 911-916		
88	MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. 2018 , 179, R19-R29		57
87	Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1821-1829	3.8	33
86	Future pharmacological therapy in hypertension. 2018 , 33, 408-415		8
85	A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). 2018 , 38, 962-969		50
84	Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone. 2018 , 122, 606-615		50
83	Periarterial fat from two human vascular beds is not a source of aldosterone to promote vasoconstriction. 2018 , 315, F1670-F1682		8
82	Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses. 2018 , 14, 233-246		2
81	Resistant Hypertension. 2018 , 398-408		0
80	Mineralocorticoid receptor antagonism prevents obesity-induced cerebral artery remodeling and reduces white matter injury in rats. 2018 , 25, e12460		6
79	Effects of eplerenone on blood pressure and glucose metabolism in Japanese hypertensives with overweight or obesity. 2019 , 98, e14994		1
78	leaf extract facilitates oligodendrocyte development. 2019 , 6, 190266		2

77	Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. <i>Hypertension Research</i> , 2019 , 42, 1932-1941	4-7	25
76	Formulation and Characterization of Eplerenone Nanoemulsion Liquisolds, An Oral Delivery System with Higher Release Rate and Improved Bioavailability. 2019 , 11,		18
75	Mineralocorticoid Receptor Antagonists. 2019 , 109, 151-188		3
74	Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. 2019 , 20, 171		9
73	Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. 2019 , 33, 542-551		24
72	Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?. <i>Current Hypertension Reports</i> , 2019 , 21, 22	4-7	11
71	Real-World Strategies to Treat Hypertension Associated with Pediatric Obesity. <i>Current Hypertension Reports</i> , 2019 , 21, 18	4-7	6
70	Pharmacokinetics, Metabolism, and Excretion of [C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans. 2019 , 47, 340-349		20
69	Abiraterone and spironolactone in prostate cancer: a combination to avoid. 2019 , 74, 439-444		6
68	Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism. 2019 , 118, 72-82		12
67	New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. 2020 , 33, 37-48		24
66	Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial. 2021 , 47, 101190		5
65	Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism. 2020 , 26, 1416-1424		8
64	Effects of Eplerenone on Blood Pressure and Echocardiographic and Serum Biochemical Variables in Five Healthy Dogs: A Pilot Study. 2020 , 2020, 5193856		
63	Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. 2021 , 35, 148-156		17
62	Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. <i>Hypertension Research</i> , 2021 , 44, 371-385	4-7	6
61	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. 2021 , 42, 152-161		82
60	Pathology of Aldosterone Biosynthesis and its Action. 2021 , 254, 1-15		3

59	Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. 2021 , 12, 625457	2
58	Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design. 2021 , 31, 83-88	
57	Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology. 2021 , 9,	3
56	Future of Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Nephropathy. 2021 , 16, 157-163	
55	Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. 2021 , 14,	5
54	Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease. 2021 , 77, 685-698	2
53	Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study. 2021 , 12, 2485-2498	3
52	Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease. 2021 , 6, 2281-2291	4
51	Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy. 2021 , 172, 105859	6
50	Antihypertensive Drugs. 2012 , 1824-1878	1
49	Aldosterone receptor blockade: a therapy resurrected. 2003 , 5, 85-8	4
48	Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling. 2021 , 106, 1195-1208	6
47	Interfering with mineralocorticoid receptor activation: the past, present, and future. 2014 , 6, 61	6
46	Many-to-one comparisons after safety selection in multi-arm clinical trials. 2017 , 12, e0180131	2
45	Endothelial mineralocorticoid receptor ablation does not alter blood pressure, kidney function or renal vessel contractility. 2018 , 13, e0193032	14
44	Future Anti-aldosterone Agents. 2018 , 24, 5548-5554	1
43	Eplerenone: The Multifaceted Drug in Cardiovascular Pharmacology. 2020 , 12, 381-390	2
42	Secondary Hypertension: Adrenal and Nervous Systems. 2003 , 127-154	

- 41 Mineralocorticoid Receptor Antagonists. **2005**, 736-746
- 40 Initial Choices in the Treatment of Hypertension. **2005**, 507-511
- 39 Adrenal Cortex Hypertension. **2005**, 792-806
- 38 Hypertension and ethnic group: eplerenone may have role in hypertension related atrial fibrillation. **2006**, 332, 974
- 37 Heart Failure in Hypertension. **2007**, 340-350
- 36 Endocrine Toxicology. **2007**, 317-345
- 35 Pharmacologic Treatment of Hypertension. **2007**, 578-599
- 34 Drug-induced Alterations of Sodium Balance: The Example of Nonsteroidal Anti-inflammatory Agents. **2007**, 399-414
- 33 Primary Hyperaldosteronism. **2009**, 365-377
- 32 Chapter 11 Diuretics in hypertension. **2009**,
- 31 5.?????????????????????????????????. **2009**, 40, 515-525
- 30 Chapter 16 Other antihypertensive agents. **2009**,
- 29 Primary Mineralocorticoid Excess Syndromes and Hypertension. **2010**, 1959-1979
- 28 Aldosterone and Cardiovascular Diseases. **2014**, 155-196
- 27 Practical Pearls in the Treatment of Hypertension in Blacks. **2015**, 213-232
- 26 [Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015]. *Terapevticheskii Arkhiv*, **2015**, 87, 77-83 0.9
- 25 Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. *Frontiers in Pharmacology*, **2021**, 12, 754239 5.6 1
- 24 Novel Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Disease. *British Journal of Pharmacology*, **2021**, 8.6 10

23	Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-17	5.9	3
22	Effect of diuretics on plasma aldosterone and potassium in primary hypertension: A systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	0
21	Real world comparison of spironolactone and eplerenone in patients with heart failure.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	0
20	Mineralocorticoid Receptor Antagonist Treatment of Established Pulmonary Arterial Hypertension Improves Interventricular Dependence in SU5416-Hypoxia Rat Model.. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022 ,	5.8	0
19	Eplerenone: A novel Mineralocorticoid receptor antagonist for the clinical application. <i>Environmental Disease</i> , 2022 , 7, 1	0.2	
18	High Prevalence of Autonomous Aldosterone Production in Hypertension: How to Identify and Treat It.. <i>Current Hypertension Reports</i> , 2022 , 1	4.7	0
17	Aldosterone-Induced Sarco/Endoplasmic Reticulum Ca Pump Upregulation Counterbalances Ca ²⁺ -Mediated Ca Influx in Mesenteric Arteries.. <i>Frontiers in Physiology</i> , 2022 , 13, 834220	4.6	1
16	Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism.. <i>Hypertension Research</i> , 2021 ,	4.7	0
15	The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.. <i>Current Hypertension Reports</i> , 2022 , 1	4.7	1
14	Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism. <i>Hypertension Research</i> ,	4.7	1
13	Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial.		0
12	Mineralocorticoid receptor antagonism improves transient receptor potential vanilloid 4-dependent dilation of cerebral parenchymal arterioles and cognition in a genetic model of hypertension. 2022 , 40, 1722-1734		1
11	Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure. 17, 12		0
10	How Do I Optimize Heart Failure Medications for Patients with Hypotension or Chronic Kidney Disease?. 2022 , 1,		0
9	Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.		0
8	A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction.		0
7	Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?.		0
6	Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus. 2022 , 6, 536-551		1

5	Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure. 2023 , 3, 56-72	0
4	Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. 2023 , 41, 295-302	2
3	Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. 2023 , 10, 205435812211505	1
2	Unilateral adrenalectomy in bilateral adrenal hyperplasia with primary aldosteronism. 2023 , 122, 393-399	0
1	Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial. 2023 , 23,	0